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Tumor hypoxia is relevant for tumor growth, metabolism, resistance to chemotherapy and
metastasis. We have previously shown that hyperoxia, using hyperbaric oxygen treatment
(HBOT), attenuates tumor growth and shifts the phenotype from mesenchymal to epithelial
(MET) in the DMBA-induced mammary tumor model. This study describes the effect of
HBOT on tumor growth, angiogenesis, chemotherapy efficacy and metastasis in a triple
negative MDA-MB-231 breast cancer model, and evaluates tumor growth using a triple posi-
tive BT-474 breast cancer model.
Materials and methods
5 x 105 cancer cells were injected s.c. in the groin area of NOD/SCID female mice. The BT-
474 group was supplied with Progesterone and Estradiol pellets 2-days prior to tumor cell
injection. Mice were divided into controls (1 bar, pO2 = 0.2 bar) or HBOT (2.5 bar, pO2 = 2.5
bar, 90 min, every third day until termination of the experiments). Treatment effects were
determined by assessment of tumor growth, proliferation (Ki67-staining), angiogenesis
(CD31-staining), metastasis (immunostaining), EMT markers (western blot), stromal com-
ponents collagen type I, Itgb1 and FSP1 (immunostaining) and chemotherapeutic efficacy
(5FU).
Results
HBOT significantly suppressed tumor growth in both the triple positive and negative tumors,
and both MDA-MB-231 and BT-474 showed a decrease in proliferation after HBOT. No dif-
ferences were found in angiogenesis or 5FU efficacy between HBOT and controls. Never-
theless, HBOT significantly reduced both numbers and total area of the metastastatic
lesions, as well as reduced expression of N-cadherin, Axl and collagen type I measured in
the MDA-MB-231 model. No change in stromal Itgb1 and FSP1 was found in either tumor
model.
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Conclusion
Despite the fact that behavior and prognosis of the triple positive and negative subtypes of
cancer are different, the HBOT had a similar suppressive effect on tumor growth, indicating
that they share a common oxygen dependent anti-tumor mechanism. Furthermore, HBOT
significantly reduced the number and area of metastatic lesions in the triple negative model
as well as a significant reduction in the EMT markers N-cadherin, Axl and density of collagen
type I.
Background
Breast cancer is the leading cause of cancer death among women worldwide and 90% of breast
cancer deaths are due to metastasis [1]. The prognosis of breast cancer is classified by variables
such as histological type, grade, stages and receptor status. The receptor status can be classified
as estrogen receptor-α (ER), progesterone (PR) and human epidermal growth factor 2 (HER2)
positive (also called triple positive or Luminal B).The tumors that do not express the receptors
(ER, PR or HER2) are also called triple negative tumors, while the HER2 positive and Luminal
A with ER, PR positive and HER2 negative consitute separate subgroups. The molecular sub-
types of breast cancer have been shown to predict the clinical outcome, and in particular breast
cancers expressing hormone receptors (luminal A) have a more favorable prognosis, while
women with basal-like breast cancers (including most of the triple-negative tumors) had
shorter relapse-free survival times than women with other types of breast cancer [2]. Despite
differences in taxonomy, there is a consistent trend across all studies confirming the relatively
poor prognosis of the triple-negative or basal-like breast cancer subgroup, and patients with
triple-negative breast cancer, carries the worst prognosis among all subtypes due to the highly
aggressive and metastatic potential of this subtype [3]. As such, many preclinical and clinical
studies have focused on developing effective therapeutics for this group of patients.
The main features of metastasis is that primary tumor cells migrate to and invade distant
sites through multiple steps. Accumulating evidence has shown that the hypoxic tumor micro-
environment plays a key role in regulating breast cancer progression and metastasis, in partic-
ular via hypoxia-inducible factor 1 (HIF-1), a master regulator of the hypoxic response [4].
Enhanced oxygen tension will degrade HIF-1 and thereby shut off genes that are generally
stimulated by the hypoxic tumor microenvironment [5]. In addition, hypoxia is considered to
be important for initiating the epithelial-mesenchymal transition (EMT), where cancer cells
lose key epithelial markers such as E-cadherin and obtain mesenchymal markers including
N-cadherin. Tumor cells undergoing EMT change morphology from a cobble-stone like phe-
notype to a flat and spindle-shaped mesenchymal type with high level of motility proteins,
enabling invasion, extravasation and metastatic niche formation [6]. Thus, there is a close rela-
tionship between hypoxia and tumor metastasis.
Hypoxia is considered critical for tumor progression. Our group has previously shown that
the opposite, hyperoxia (HBOT-hyperbaric oxygen treatment) attenuates or significantly
reduces breast cancer growth using a chemically induced (DMBA) (triple positive) model and
a murine triple negative (4T1) adenocarcinoma model [7–11]. Furthermore, our studies dem-
onstrated that hyperoxia induced a mesenchymal-to-epithelial transition (MET) in the DMBA
breast cancer model [12]. These findings, together with a significantly decreased collagen
deposition in the tumors, indicated that HBOT induced a less aggressive tumor behavior [12].
In addition, a study showed a reduction in tumor interstitial pressure with a concomitant
increase in uptake of the chemotherapeutic agent 5FU after HBOT [8].
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Thus, the present study aimed to investigate the effect of HBOT on tumor growth of two
different receptor subtypes of human breast tumors; the triple positive BT-474 and the triple
negative MDA-MB-231 model. In addition, the effect of HBOT on 5FU efficacy, as well as the
development of metastatic lesions was investigated in the latter model.
Materials and methods
The cell-lines and culture
The human breast cancer cell lines, MDA-MB-231 and BT-474 were obtained from American
Type Culture Collection (Rockville, MD, USA) and grown in F12K (Bio-Whittaker, Verviers,
Belgium) or RPMI medium, respectively, supplemented with 100 ml/L of fetal calf serum, 100
U/L of penicillin and 100 mg/L of streptomycin (Sigma-Aldrich, Steinheim, Germany). The
cells were amplified as a monolayer in plastic tissue culture flasks 75 cm2 (NUNC, Roskilde,
Denmark) in a humidified incubator set at 37˚C with 5% CO2 and 95% air, and were seeded
until approximately 80% confluence.
Animals
Female NOD/SCID mice (Jackson Laboratory, USA), age 7–10 weeks, weighing 20–25 g were
used. The mice were kept in individually ventilated, pathogen-free cages where they had free
access to food and water ad libitum. All the experiments were approved by the Norwegian
Committee for Animal Research (FOTS project number: 23135440). Bodyweight, activity,
tumor size and skin changes were monitored carfully throughout the experiments. No animals
showed any signs of illness following tumor formation and metastasis and none died due to
the experimental procedure.
Mouse model for human breast cancer xenografts
For the xenograft experiments, 5 x 105 tumor cells, in 0.15 ml PBS were injected subcutane-
ously on one side and into the fat pad of their mammary crest in the groin area. For the BT-
474 xenograft, sixty-day release pellets containing 17β-Estradiol (1.7 mg) and progesterone (10
mg) (Innovative Research of America, Sarasota, FL) were implanted subcutaneously in the
neck 2 days prior to injecting the cells. By day 8, when 100% of the mice had developed palpa-
ble tumors, they were assigned to either hyperbaric oxygen treatment (HBOT) or control.
Tumor volume was measured every three days using a caliper. The location of the tumor
only allowed measurements in two dimensions. The best estimate of tumor volume given
these restrictions was a calculation based on a cylindrically shaped tumor according to the fol-
lowing equation: Tumor volume (mm3) = (short axis)2 x (long axis) x (π/6).
After completion of the study, the mice were sacrificed with CO2 when fully anesthetized
using Ketalar-Dormicum and the whole tumor was excised and processed for subsequent
immunohistochemistry and western blot analysis.
Hyperbaric oxygen treatment (HBOT)
A hyperbaric animal research chamber (27 liter, OXYCOM 250 ARC, HYPCOMOY, Tam-
pere, Finland) was used. The chamber was flushed with pure O2 for approximately 15 minutes
at normal ambient pressure. The pressure was then slowly increased from 1 to 2.5 bar (equiva-
lent to 15 msw) during approximately 10 minutes, and was kept stable at this pressure for
another 90 minutes. To ensure levels above 97%, the chamber was flushed with pure O2 every
10 minutes for 5 min. After the treatment the chamber was slowly decompressed to 1 bar over
a period of approximately 15 minutes. The mice underwent this treatment on days 1, 4, 7, 10,
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13 and 16. Day 1 (starting measurements) was set as being 8 days after the injection of tumor
cells. For the separate metastatic study, the mice underwent 17 treatments, i.e. every third day,
during the whole 54 day period.
5-Fluorouracil (5FU)
To evaluate if HBOT could potentiate drug efficacy, the chemotherapeutic drug Fluorouracil,
5FU (50 mg/ml, Hospira Nordic AB, Stockholm, Sweden) was administered i.v. at a dose of 1.5
mg/kg in a volume of 0.1 ml as a stand-alone treatment or in combination with HBOT. In the
latter case it was given immediately prior to each HBOT for optimal effect.
CD31-staining
On the last day of measurements, the tumors were quickly dissected out, snap-frozen in liquid
nitrogen and stored at –80˚C until further use. The frozen tumor tissue was embedded in Tis-
sue Tek (Sakura Fintek Europe, Zoeterwounde, the Netherlands) and cut into 10–20 μm slices
with a cryostat microtome (Leica CM 3050 S-Cryostat, Nussloch, Germany). Blood vessels in
the frozen slides of tumor (10 μm) were immunostained with rat anti-mouse CD31 (1:200)
(AbD serotec, Morphosys UK Ltd, Oxford, UK) as primary antibody. Biotinylated rabbit-anti-
rat (Vectastatin ABC kit, peroxidase Rat IgG PK 4004, Bioteam AS, Trondheim, Norway) was
used as secondary antibody. Rabbit serum was used as a blocking agent and H2O2 in methanol
was used to quench endogenous peroxidases. An avidin biotin peroxidase complex was used
to bind to the biotinylated secondary antibody. The chromogen DAB was used to visualize the
blood vessels (DAB, Sigma-Aldrich, Germany). Richardsson’s stain was used to counterstain
the rest of the tumor tissue. The cross-section of CD31 positive structures was quantified per
mm2 of the entire tumor. The blood vessel diameter was also measured. The Computer-soft-
ware program NIS-Elements AR 3.2 64-bit (Laboratory Imaging Ltd, Prague, Czech Republic)
was used for this purpose. Also, for standard histologic examination of the tumor specimens,
frozen sections from both HBOT tumors and controls were stained with Haematoxylin-Eosin.
Ki67-staining
Ki67-staining was carried out on 10 μm thick cryosections from the control group and the
HBOT group. Sections were fixed for 8 minutes in 70% methanol and 30% acetone at -20˚C,
and further washed 3 x 10 min in PBS. Unspecific binding was blocked with Peroxidase Block
from the Dako EnVision+ System-HRP (DAB+) kit (K4006, Dako, Glostrup, Denmark) for 8
minutes, before washing the sections 2 min x 3 in PBS. The primary antibody, Monoclonal
Mouse Anti-Human Ki67 (M7240, Dako, Glostrup, Denmark), was diluted 1:75 in Antibody
Diluent with Background Reducing Components (S3022, Dako, Glostrup, Denmark), and
the sections were incubated 1 hr at RT. Thereafter, the sections were washed 5 min x 2 with
PBS-T, and 5 min x 1 with PBS. The Peroxidase Labeled Polymer from the Dako EnVision+
System-HRP (DAB+) kit (K4006, Dako, Glostrup, Denmark) was applied and incubated for 30
min at RT, before washing 5 min x 2 with PBS-T. Liquid DAB+ Chromogen and buffer from
the Dako EnVision+ System-HRP (DAB+) kit (K4006, Dako, Glostrup, Denmark) was mixed
as described by manufacturer, and incubated on sections for 1 min and 50 sec. Sections were
immediately washed in ddH2O for 3 min. Hematoxylin was used as a counterstain, with 3 min
incubation prior to 3 min wash in 37˚C running water. Sections were dehydrated for 10 sec in
each bath in the following order; 75% ethanol, 96% ethanol, 96% ethanol, 100% ethanol, 100%
ethanol, Xylol, Xylol. Finally, the sections were mounted with coverslips using Hecht KarlTM
Assistent Histokitt (Fisher Scientific, Göteborg, Sweden). Images were captured and analysed
using the Nikon Eclipse E600 microscope, and the computer program NIS-Elements AR 3.2
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64-bit (Laboratory Imaging Ltd, Prague, Czech Republic). Ki67 positive cells were counted as
positive cells per mm2.
Immunofluorescence (IF) staining of tissue sections
IF staining was performed on cryosections of tissue samples from mice treated with or without
HBO for 24 days (5 mice from each group). Sections with a thickness of 10 μm were fixed in
methanol for 10 minutes at -20˚C and then rehydrated in PBS (3x10 min). Unspecific binding
sites were blocked with 10% goat serum diluted in PBS for 1 h at room temperature. Thereaf-
ter, the sections were incubated with primary antibody against integrin β1, rat anti-mouse
(Millipore MAB1997, dilution 1:400), rabbit anti-FSP1 antibody (Millipore 07–2274, dilution
1:400), rabbit anti-mouse collagen type I (Millipore AB765P, dilution 1:200), rabbit anti-
human cytokeratin-7 (Novus Biologicals NBP1-30152, dilution 1:400) or mouse anti-human
cytokeratin (clones AE1/AE3, Dako M3515, dilution 1:400) for 1 h at 37˚C. After two washing
steps with PBS/0.05% Tween and an additional washing step with PBS, the secondary antibod-
ies were applied. Alexa Fluor1 488 Goat Anti-Rat (Jackson ImmunoResearch Cat.112-545-
003, dilution 1:800) was used for integrin β1, Alexa Fluor1 594 Goat Anti-Rabbit (Jackson
ImmunoResearch Cat.111-585-144, dilution 1:800) was used for collagen type I or cytokera-
tin-7. The sections were incubated with the secondary antibody for 1 h at room temperature.
Sections stained with secondary antibody only were used as negative controls. After two wash-
ing steps in PBS/0.05% Tween, sections were mounted in ProLong1 Gold Antifade Mountant
with DAPI (ThermoFisher P36935) and were dried overnight. Afterwards, the mounted sec-
tions were observed under a Zeiss Axioscope fluorescence microscope and photographed
using a digital AxioCam mRM camera (Zeiss). Four to five sections from each tumor was used
for analysis using the software program Image J (National Institite of Health, MD, USA).
For IF staining to evaluate Axl RTK and N-cadherin, cryosections were air dried 40 min at
room temperature (RT), and subsequently fixed in 3.7% formalin for 10 min, RT. Sections
were washed 2 x 5 min with PBS, and incubated with 0.5% Triton X-100 in PBS, 4 min, RT.
Following 2 x 5 min washes, sections were blocked with 5% goat serum, 1% BSA and 0.1% Tri-
ton X-100 in PBS for 1 h, RT. Sections were incubated with primary antibodies over night at
4˚C; mouse anti human Axl (1H12, BerGenBio AS, dilution 1:150), rabbit anti human N-cad-
herin (Abcam, ab18203, 1:200). Following wash 3 x 10 min with 0.1% Triton X-100 in PBS,
sections were incubated with secondary antibodies for 1 h at RT; goat anti mouse-488 (A21131,
Invitrogen/Molecular probes, dilution 1:200) and goat anti rabbit 647 (A21244, Invitrogen/
Molecular probes, dilution 1:300). Sections were washed with Triton X-100 in PBS 3 x 10 min,
dipped in water and mounted with ProLong Diamond antifade mounting medium with DAPI
(P36962, Life technologies/Molecular Probes) and high precicion cover glass (No. 1014, Assis-
tent). Images were obtained on a Leica TCS SP5 confocal microscope system, equipped with a
63x HCX PL Apo Oil objective (Leica). A maximum projection snapshot of a 9 μm z-stack is
shown. The confocal microscope is available through the molecular imaging centre (MIC), a
core facility at the University of Bergen.
Metastasis
Development of metastasic lesions was studied in a separate series of experiements. Mice were
injected with 5 x 105 MDA-MB-231 cells and terminated at day 54 post-injection. The lungs
were fixed post mortem using approximately 1 mL of Bouin’s solution (Gurr BDH Chemicals
Ltd., Poole, UK) injected into the trachea. The lungs were immediately dissected out, fixated in
new Bouin’s solution, washed in 70% ethanol, dehydrated and embedded in paraffin using stan-
dard procedures. The liver and femur bone were removed and fixed in formalin immediately
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after sacrificing the animal. After fixation the bone was decalcified in 10% EDTA, pH 7.2, dur-
ing a period of 5 weeks. Sections were stained with H & E staining and examined by light
microscopy. In order to quantify lung metastasis, 4 coronal sections from both lungs from each
animal were examined. Total number of metastasis per lung was counted, and the area per lung
covered by metastasis was measured in mm2 (Nikon Digital Sight, Nikon Corporation).
Western blot
On the last day of measurements the tumors were dissected out, snap frozen in liquid nitrogen
and stored at -80˚C until further use. The MDA-MB-231 tumors were divided in two halves, and
one was used for immunohistochemistry and the other to make the proteinlysate for western blot.
Briefly, a cross section (approximately 50 mg) of tumor tissue was homogenized in denaturing
lysis buffer (DLB), containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Trition X, complete
EDTA free tablet and phosphatase inhibitor, with homogenizing beads in a tissue homogenizer
(Precally1 24, Bertin Technologies, France) for 6,800-3x10-30 at 4˚C and incubated on ice for 45
min. The lysate was removed and centrifuged at 12,000 rpm for 10 min at 4˚C (Eppendorf 5415R,
Hamburg, Germany). The supernatant was collected, aliquoted and stored at -80˚C. The protein
concentration was determined by a BCA assay (PierceTM, Thermo Scientific, Rockford, USA),
according to the manufacturer’s protocol. Equivalent concentrations were run on a 12% gel
under reducing conditions with 50 mM DTT in sample buffer, and transferred using iBlotTM
(Invitrogen, Life Technologies, Carlsberg, CA, USA) for 10 min. Membranes were blocked with
I-block (Tropix1, Thermo Scientific, Bedford, USA) for 1 h and 30 min at RT. Rabbit anti-
mouse E-cadherin (ab 53033, diluting factor 1:800) and rabbit anti-mouse N-cadherin (ab76057,
diluting factor 1:1000) (Abcam, Cambridge, UK) were used as primary antibodies and incubated
over night at 4˚C. Membranes were washed further for 3 x 5 min in TBS-T and incubated with
secondary antibody (goat anti-rabbit IgG HRP, ab97051, diluting factor 1:5000)(Abcam, Cam-
bridge, UK) for 2 h at RT. Membranes were washed 2 x 5 min TBS-T and 1 x 5 min TBS before
development with ECL substrate (Pierce ECL Western Blotting Substrate, Thermo Scientific,
32209) chemiluminescense was measured with Molecular Imager ChemiDoc XRS+ (BIO-RAD).
The ImageLab v5.2.1 (BIO-RAD) software was used for analysis and quantification of the results.
Statistical analysis
Sigmaplot 12.5 (Systat Software inc) was used for statistical analysis. Either the unpaired two-
tailed t-test, or the Mann-Whitney rank sum test, was used to analyze statistical differences
between the two groups. One-way Anova for 5FU experiemenst followed by posthoc test was
used. Results were accepted as statistically significant when p< 0.05.
Results
Growth of different molecular subtypes of breast cancer during HBOT
We assessed the anti-tumorigenic activity of HBOT compared to control on mouse xenograft
experiments using the triple negative MDA-MB-231 (n = 14) and triple positive BT-474
(n = 14) human breast cancer cell lines. The mice were exposed to either normal atmospheric
pressure or given HBOT, and the tumor volume was measured every 3 days for 17 days.
HBOT significantly (p<0.001) suppressed the tumor growth of both the triple-negative
MDA-MB-231 and triple positive BT-474 tumors during a treatment period of 17 days (24
days post injection) as indicated in Fig 1, panels A-B. The results demonstrated the inhibitory
effect of HBOT on tumor growth to be independent of breast cancer subtypes indicating a
shared oxygen dependent antitumor mechanism. The size of the MDA-MB-231 tumors were
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Fig 1. Tumor growth. The effect of hyperbaric oxygen treatment on the growth of triple negative MDA-MB-231
(p<0.001) (A) and triple positive BT-474 (p<0.001) (B) tumors. Cells were injected subcutaneously in the mammary fat
pad. Mice were treated with 2.5 bar pure oxygen, 90 min each time, every third day, during a period of 24 days
Oxygen-dependent regulation of tumor progression
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692 ± 106 mm2 and 461 ± 55 mm2 in controls and HBOT mice respectively at day 53 (final
day) in the separate metastatic study.
HBOT significantly reduced the number of proliferating cells
Ki67-staining, presented in Fig 2, revealed a significantly higher number of proliferating cells
in the control group compared to the HBOT group, with an average of 363 (n = 4) and 28
(n = 3) positive cells per mm2, respectively (p = 0.0002) in the MDA-MB-231 group and an
average of 80.8 (n = 4) and 33.6 (n = 4) positive cells per mm2, respectively (p = 0.0001) in the
BT-474 group.
HBOT did not affect tumor blood vessel density or diameter
Since angiogenesis is known to greatly influence tumor growth, blood vessels were stained
using rat anti-mouse CD31 as primary antibody. The average tumor blood vessel density and
blood vessel diameter are given in Table 1. There was no statistically significant difference
between the HBOT tumors and controls. Based on this, we conclude that the tumor growth
suppression during HBOT is not attributed to any effect on angiogenesis in these human
tumor xenograft models.
HBOT does not enhance the 5FU efficacy
Tumor hypoxia is known to be connected to drug resistance and thus we investigated if hyperoxia
might influence the efficacy of the chemotherapeutic drug 5FU. As a stand-alone treatment, 5FU
(measurements started day 7 post injection) (closed circles) and compared to controls (open circles). Mean ± SEM.
n = 7 in each group.
https://doi.org/10.1371/journal.pone.0183254.g001
Fig 2. Proliferation. Ki67-staining revealed a significantly higher number of proliferating cells in the control group compared to the HBOT group in both
models (MDA-MB-231, * p = 0.0002. BT-474, * p = 0.0001). Scale bar 500 μm.
https://doi.org/10.1371/journal.pone.0183254.g002
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significantly reduced tumor growth in the MDA-MB-231 model as expected. Nevertheless,
HBOT did not potentiate the effect of 5FU in the present MDA-MB-231 model (Fig 3).
HBOT affects metastasis
Few studies concerning the relationship between HBOT and metastasis exists due to an old
perception that HBOT would potentiate metastasis via enhanced angiogenesis. Thus, to
Table 1. Blood vessels.
MDA-MB-231 BT-474
Controls HBO Controls HBO
Pressure pO2 1 bar 2.5 bar 1 bar 2.5 bar
% O2 20 100 20 100
Blood vessels density (number/mm2) 13.5 ± 1.6 12.4 ± 1.8 11.1 ± 2.2 13.1 ± 4.5
Blood vessel diameter (μm) 7.3 ± 1.7 7.2 ± 1.8 12.0 ± 6.1 12.3 ± 6.4
Blood vessel density and diameter in MDA-MB-231 and BT-474 tumors in control and after hyperbaric oxygen treatment for 24 days. Means ± SD.
https://doi.org/10.1371/journal.pone.0183254.t001
Fig 3. 5-Fluorouracil. The effect of hyperbaric oxygen treatment (HBOT) (n = 10), the chemotherapeutic drug 5FU (1.5 mg/kg in
0.1 ml) (n = 10) or 5FU in combination with HBOT (n = 10) on growth of MDA-MB-231 human mammary tumors over a period of
17 days. *p<0.05.
https://doi.org/10.1371/journal.pone.0183254.g003
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evaluate whether HBOT has an effect on the metastatic potential of triple negative MDA-MB-231
tumors, H & E stained organ sections were evaluated. Macroscopic surface metastases were
observed in all the lungs from both HBOT and control mice (Fig 4). However, there was a signifi-
cant difference in the ability of primary tumor cells to metastasize to the lungs between the HBOT
and controls (Fig 5). The number, as well as the area of the metastatic lesions were significantly
reduced in the HBOT group (Fig 5, panels A-B). No metastatic lesions in liver nor bone were
detected in either group at the time the experiements were terminated (54 days post injection).
The effect of HBOT on Epithelial to Mesenchymal Transition (EMT)
signalling
EMT has been indicated to play an important role in the development of cancer and metastasis
and thus the specific markers E-Cadherin and N-Cadherin were investigated using western
blot. Immunoblots from MDA-MB-231 tumor lysates indicated a downregulated N-cadherin
expression in HBOT tumors. The downregulated N-cadherin in HBOT tumors was confirmed
Fig 4. Metastases. A representative picture of the metastatic lung in the MDA-MB-231 tumor model 54 days post injection is shown.
https://doi.org/10.1371/journal.pone.0183254.g004
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by volume density data, and statistical analysis showed a significant difference (p<0.02) as
indicated in Fig 5. Although there was a tendency of enhanced E-cadherin expression, there
were no statistically significant expression differences between the two groups (Fig 6). Immu-
nofluorescence of cryosections from HBOT and control tumors verified the downregulation
of N-cadherin in the HBOT tumors, and further revealed that N-cadherin was mainly localized
to the nucleus in the MDA-MB-231 tumors. Finally, the expression of Axl was significantly
downregulated (Fig 6).
Effects of HBOT on collagen content and proportion of stroma versus
tumor cells
Analysis of immunoflouresent stained collagen type I fibrils in primary tumors, using Image J,
revealed significant (p<0.001) reduced density in HBOT compared to controls as shown in
Fig 5. Lung metastases after hyperbaric oxygen treatment. The effect of hyperbaric oxygen treatment on the metastatic development of triple
negative MBA-MB-231 breast cancer cells in vivo after 54 days. 5 x 105 cells were injected in the mammary fat pad in the groin area. Mice were treated
with 2.5 bar pure oxygen, 90 min each time, every third day starting 7 day post injection over a period of 54 days. Histomorphometric quantification of
metastasis number (A) and area (B) in H&E stained lung sections of HBOT and controls is shown. Mean ± SD. *p<0.02. A representative lung section
from one control (C) and HBOT (D) is shown.
https://doi.org/10.1371/journal.pone.0183254.g005
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Fig 6. Epithelial to mesenchymal transition after hyperbaric oxygen treatment. MDA-MB-231 tumors constitutively express E-
cadherin (A) and N-cadherin (C) in western blot lysates in both groups. The expression of E-cadherin (B) and N-cadherin (D) when
adjusted according to loading control (β-Actin) in control (n = 5 tumors) and HBOT (n = 5 tumors) is also shown. Mean ± SD. *p>0.05.
Immunofluorescent staining of cryosections from HBOT and control MDA-MB-231 tumors confirm the reduced nuclear N-cadherin and
also reveals a reduction in the expression of receptor tyrosine kinase Axl (E). Scalebar: 25μm.
https://doi.org/10.1371/journal.pone.0183254.g006
Oxygen-dependent regulation of tumor progression
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Fig 7. Collagen type I. The total amount of collagen type I quantified as percent of total area in both control (n = 5 tumors) and HBOT (n = 5 tumors)
primary tumors (A) is shown. The total amount of ITGB1 as percent of total area in both control (n = 5 tumors) and HBOT (n = 5 tumors) primary tumors
(B). A representative immunofluorescence (IF) staining picture from a control (C) and HBOT (D) tumor is shown. Green represents stroma cells (stained
with antibody to mouse integrin-β1) red represents collagen type I secreted by the stromal cells (stained with antibody to mouse collagen type I), and blue
shows the nuclei stained with DAPI. Scale bar represents 100 μm. Representative IF pictures are also shown to illustrate the compostion/proportion of the
Oxygen-dependent regulation of tumor progression
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Fig 7, panels A, C-D. Analysis of immunoflouresent stained Itgb1 did not show any differenes
between controls and HBOT (B), neither did FSP1 as shown in S1 Fig. The amount of stroma
versus tumor cells are also demonstrated in Fig 7, panels E-F, demonstrating significantly less
cancer cells in the HBOT group compared to control.
Discussion
The present study demonstrated a strong and similar primary tumor growth suppressing effect
of HBOT (2.5 bar, 100% O2, a 90 min) in both triple negative and triple positive human breast
cancer xenografts in mice during a period of 24 days post tumor cell injection, which is sup-
ported by a reduction in proliferation. There was however no change in angiogenesis, nor
potentiating effect on the chemotherapeutic agent 5FU. The triple negative MDA-MB-231
model showed a significantly reduced number of metastasis, as well as a reduced area of the
metastatic lesions following HBOT, with a concomitant reduction in the EMT marker N-Cad-
herin, Axl and collagen type I.
Intratumoral hypoxia is known to have negative implications for breast cancer development
and is associated with a more aggressive phenotype which potentiates growth, metastasis and
resistance to chemotherapy as well as radiotherapy [13, 14]. Hypoxia, via HIF-1a, causes trans-
location to the nucleus and increase the transcription of multiple genes associated with this
aggressive behaviour. Thus, since HBOT enhanced the pO2 in tissues temporarily, and O2 is
important for degrading HIF-1a, we expected reduction in tumor growth.
HBOT is commonly used for treatments including wound healing, tissue regeneration as
well as after radiation injury, to enhance the pO2 in the otherwise hypoxic tissue [15]. The
present study showed significant tumor growth suppression after HBOT in both the human
MDA-MB-231 and BT-474 breast cancer model. Thus, enhanced oxygenation in the present
study has been shown to induce a similar anti-cancer effect in both triple positive and triple
negative breast cancers. This HBOT effect on tumor growth corresponds to what has previ-
ously been found in our laboratory in both chemically induced (DMBA) [9, 10, 12] and
murine 4T1 [8, 11, 16] mammary tumors. Kluft et al. [17] showed significant inhibition of
transplanted mammary carcinomas in C57 black mice after HBOT, and a strong anti-prolifer-
ative effect on different mammary cancer cells has been shown in vitro [18]. HBOT in the pres-
ent study could confirm a strong anti-proliferating effect in both mammary models. Thus,
HBOT seems to have a strong suppressive and/or inhibitory effect on mammary tumors in
general.
HIF-1a is a key oxygen-regulator of VEGF gene expression which is important for angio-
genesis and thus tumor growth [19]. Differences in tumor blood vessel density is therefore
one possible cause for the differences in size between the controls and HBOT measured in
MDA-MB-231 and BT-474 tumors. Although an anti-angiogenesis effect of HBOT has previ-
ously been found in other breast cancer models [8, 9] and gliomas in vivo [20], the blood vessel
density and diameter was unchanged in the two human breast cancer models investigated in
the present study. We therefore concluded that the anti-tumor effect found, in these two
human breast tumor models after HBOT is not due to anti-angiogenesis. It could potentially
be due to reduced proliferation of tumor cells, as shown in DMBA mammary tumors in vivo
[9, 12] and in vitro in different mammary tumor cells [18] after HBOT. This is also indicated
by the proportion of stroma/tumor between the two groups in the present study and it could
also be due to enhanced apoptosis as shown previously after HBOT [9, 12].
tumor cells (red, stained with cytokeratin 7 antibody) and the stromal cells (green, stained with integrin β1 antibody) from the control (E) and and HBOT
(F) tumors, respectively. Scale bar represents 100 μm.
https://doi.org/10.1371/journal.pone.0183254.g007
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No potentiating effect on 5FU
HBOT is used as an adjuvant treatment for various diseases and pathological conditions and it
is shown to overcome hypoxia in tumors [21]. HBOT has previously been demonstrated to
enhance the effect of chemotherapeutics in different solid tumors [10, 12, 22–25]. Thus, since
conventional chemotherapy is the mainstay adjuvant systemic treatment for early triple nega-
tive patient, we investigated whether it it could be potentiated by HBOT. However, the com-
bined HBOT and 5FU therapy caused approximately the same degree of tumor growth
inhibition as HBOT alone in the present MDA-MB-231 model. Thus, HBOT did not potenti-
ate the uptake nor enhance the effect of chemotherapy in the triple-positive MDA-MB-321
tumor model. This indicates that HBOT influences the effect of 5FU differently in different
tumor models, for reasons currently unknown.
Metastasis
There are only a few studies on HBOT and metastasis likely due to an old perception that it
would facilitate tumor growth and spread. The present study on the very aggressive, highly
metastatic, triple-negative MDA-MB-231 tumors showed a significant reduction in both num-
ber and area of metastasis after sixteen, 90 min HBOT at 2.5 ATA. This is in accordance with a
study on triple negative 4T1 murine breast cancer showing a decrease in lung colonies after
HBOT (2.8 ATA) [26] and similarily in a study on rats (3 ATA) with intravenous tumor cell
injection, where it was found a strong reduction in metastasis of the lung but no effect on
tumor cells in the hind leg. They suggested that the response was due to a local oxygen effect in
the lung [27]. Reduction in metastasis has also been found after HBOT in the lungs after i.v.
injection of mammary gland-derived carcinoma cells [28] and in mice with murine LM8 oste-
osarcoma tumours after HBOT [29]. Based on the above, we argue that it is important to re-
evaluate the effect of HBOT on metastatic potential since it seems to have a strong suppressive
effect on at least lung metastasis in different animal breast cancer models.
Advanced stages of cancer is associated with extensive deposition of collagen, particular
type I, in the ECM surrounding the tumor cells [30]. Collagen I is the principal collagen sub-
type in breast cancer and a high collagen fiber density is associated with aggressive disease and
stimulation of tumor cell migration [31]. One reason for the reduced number and area of
metastases after HBOT could therefore be the significant reduction in collagen I found after
HBOT in the present study. Since there was no difference in Itgb1 nor in fibroblasts using
FSP1 between control and HBOT we belive that the lower collagen production in HBOT
tumor samples may be due to the ratio change of the collagen-producing stromal cell, like
CAFs, rather than the change in total number of stromal cells. Hypoxia has been shown to be
involved in Epithelial-Mesenchymal Transition (EMT) in different cancers in vivo [32, 33].
EMT is identified by epithelial cells changing their originally stable cobble-stone morphologi-
cal appearance, their cell-cell adhesion properties and lack of motility to a more elongated
shape with motile, invasive features [34]. Tumor progression and invasion are associated with
this enhanced capacity to promote extracellular matrix remodelling and thus migration [35].
Cells with mesenchymal properties can be identified by the loss of epithelial markers such as
E-cadherin, and increased expression of key mesenchymal markers, such as N-Cadherin,
Snail, Twist and Vimentin [36, 37]. Previously we have shown HBOT to induce total mesen-
chymal to epithelial transition (MET) in DMBA tumors in rats [12] indicating a shift towards
a less aggressive phenotype. In the present MDA-MB-231 model, we found a significant reduc-
tion in N-cadherin after HBOT. In most types of cancer, high N-cadherin expression correlates
with cell motility, invation and metastasis [38]. Furthermore, N-cadherin was demonstrated to
be localized to the nucleus in our experimental tumor model, and aberrant N-cadherin in the
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nucleus has been shown to be necessary for cell migration during EMT [39]. And although
nuclear localisation of N-cadherin has rarely been described in human solid tumors, it has
been shown to correlate with poor prognosis in nasopharyngeal carcinoma (NPC) [40]. In this
study, a high expression of nuclear N-cadherin predicted a poorer survival in patients with late
stage disease, and multivariate analysis showed nuclear N-cadherin to be an independent prog-
nostic marker for NPC patients. We also demonstrated a reduction in the expression of Axl
RTK in the HBOT tumors. Axl RTK has been correlated with poor outcome and drug resis-
tance in a wide range of cancer types, and has been shown to be necessary for maintaining
tumor EMT [41]. Axl RTK has been shown to be upregulated in human breast cancer samples,
and to be associated with a reduced patient survival [42, 43]. Furthermore, Axl RTK expression
remained an independent negative prognostic factor in a multivariate analysis including basic
prognostic factors, and a hazard ratio of 3.27 were detected between cases with high and low
Axl expression [43]. In an experimental tumor model, the authors demonstrated that Axl
knockdown completely prevented the spread of highly metastatic breast carcinoma cells from
the mammary gland to lymph nodes and several major organs and increased overall survival.
Taken together, it is likely to assume based on the findings from our study that enhanced oxy-
gen could be critically involved in MET transition of developing breast tumors, and also be
implicated in the reduced metastatic potential observed after HBOT in the present study.
Conclusion
Despite the different behavior and prognosis of the triple positive and triple negative subtypes
of breast cancer, the HBOT had a strong and similar primary tumor growth suppressive effect
on both tumor types, indicating they share a common oxygen dependent anti-tumor mecha-
nism. Furthermore, the triple negative model showed significantly reduced number and area
of metastases after HBOT with a reduction in the EMT markers, N-cadherin, Axl and collagen
type I. Thus, as hypoxia is a negative prognostic factor for breast cancer patients, hyperoxia
may provide a favourable adjuvant therapeutic approach for breast cancer growth and progres-
sion which should be evaluated further.
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